Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I am an old $AMBS investor, since 2012. He did many mistakes on the financial side (toxic debts) and communication side. He pumped a lot the AMBS pipeline, very unusual behavior for a CEO. Even worst, no updates since too much time. For sure he didn't have the correct experience at that time.
That being said, I continued to follow him and I jumped in Todos as well. I agree with you. Your summary of the opportunities is right. I expect to see better moves in the future. It is also a matter of visibility, OTC doesn't help.
I know perfectly the risk we are running.
It is a matter of reputation and reliability of the management.. same great announcements in the past for $AMBS..
Sorry.. I didn't want to write two question marks.. I just digited an emoticon on my smartphone but it didn't work evidently
Where do you pick this info?
Hopefully they will stop as some payment will come and not just announcements..
Hello, based on what those 66M? I didn't see a corporate business plan so far and regular updates about how the business is going. I am AMBS shareholder since 2012..
Which news? The past is full of supposed "good" news.. It is only about reliability of the speaker.. I am 99% down..
Unfortunately nothing to do with AMBS, no news from GC..
Where is an updated corporate presentation? Many words.. just words
ODD And RPDD .. From AMBS website..
In December 2015, Amarantus submitted ODD and RPDD applications to the US FDA for engineered skin substitute in the treatment of Giant Congenital Hairy Nevus (GCMN), in addition to its ODD application to the US FDA for eltoprazine in the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID) submitted in October 2015. The Company expects to receive responses regarding these designation applications in the first quarter of 2016.
Is someone of you aware about others spin off occurred in the past? What will happen to our AMBS shares? I guess we don't need just a spin off but some strong partnership together with. Opinion?
It would be nice to know how many times in the past this company (seeth...) hit his forecast
Sorry this message was for jpetrolnc
Re: hnbadger1 Post# 121019
Probably someone else already asked it to you.. What is your position here? I see you post just negative thoughts about AMBS.. Are you a disappointed investor? Are you long? Do not misunderstand me, it is just to know. Have a nice day
Probably someone else already asked it to you.. What is your position here? I see you post just negative thoughts about AMBS.. Are you a disappointed investor? Are you long? Do not misunderstand me, it is just to know. Have a nice day
I keep on trusting on AMBS and I took the opportunity to really reduce my average price, it won't be a falling knife forever..
Manipulation and need of data about concrete revenues, not just forecast regarding the potential market
I suppose "qualitative" revenues because they cannot be precise till the partnership will be revealed and the marketing strategy too. Maybe they will start to anticipate something about the strategy during the conf call.. I am long but a bit disappointed because of this behaviour. Anyway I am still optmistic. GC tweetted about revenues some weeks ago. I suppose someone told him to be much more careful on tweeting or blogging.
Interesting.. thanks
I add this one http://www.quintiles.com/blog/doyle-bringing-orphan-drugs-to-market
What about the data? Still waiting for someone post it
To amend the protocol can happen because of two situations: bad news, maybe regarding the safety and they have to communicate it because of ethic rules, or really good news that they want to report to the community, to potential partners, to the scientific world. Really good news can also allow to get easier some next step. IMO
Nice article, thanks. One of the most important question will be the reimbursment. With specificity and sensibility > 90% maybe 93-94 should be not so difficult to receive it.
there are few more lines..
We look forward to completing the currently-enrolling Bridging Study that will vastly expand the Version 2 data package, and sharing top-line results in two weeks at #C4CT."
The Company is currently conducting a Version 1 vs. Version 2 Bridging Study (previously known as the Pilot Study) at BD Biosciences comparing Alzheimer's patients to cognitively intact, aged-matched controls to assess LymPro's accuracy in a head to head comparison across various univariate measurements and multivariate models. The study will provide the basis for the establishment of initial sensitivity and specificity in Version 1 and Version 2 of LymPro in the newly-analytically controlled LymPro conditions established at BD Biosciences. The Company expects to release topline Bridging Study data at the #C4CT Concussion Awareness Summit: TBI-induced Alzheimer's Disease to be held at the United Nations on July 31st.
Is anybody of you aware of previous successful cases as x 10 in few months or what usually happens in case of uplisting? Just curiosity
I am from Milan
I am long with AMBS but I am afraid 50 is too much and 5 maybe too..
means a market cap of 5 billion or 50..
said that.. I hope you will be right
GC TWEET we will be updating the market on LymPro shortly
maybe not a total swap, just a part of the previous warrants.. it's look like they negotiated again the previous conditions with some big investors
if I well understood.. it's a swap of part of the previous warrants..
if the investors accepted to swap, may be it's because they trust a lot in the company.. my opinion